Evidence map›Paper›PMID 25471523›Full record

ArticleMicrobial cell factories2014

De novo production of the monoterpenoid geranic acid by metabolically engineered Pseudomonas putida.

Jia Mi, Daniela Becher, Patrice Lubuta, Sarah Dany, Kerstin Tusch, Hendrik Schewe, Markus Buchhaupt, Jens Schrader

Open access · goldAbstract readComparative Study
In one paragraph

Article in Microbial cell factories, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 83 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Diversifying Isoprenoid PlatformsFrontiers in microbiology · 2021
    Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Rational Engineering of Phenylalanine Accumulation inFrontiers in bioengineering and biotechnology · 2019
    Article
  20. Discovery and engineering of an endophyticJournal of biological engineering · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Jia MiDECHEMA Research Institute, Frankfurt am Main, Germany. mi@dechema.de.
Daniela BecherDECHEMA Research Institute, Frankfurt am Main, Germany. danielabuchheit@hotmail.com.
Patrice LubutaDECHEMA Research Institute, Frankfurt am Main, Germany. patrice.lubuta@outlook.com.
Sarah DanyDECHEMA Research Institute, Frankfurt am Main, Germany. dany@dechema.de.
Kerstin TuschDECHEMA Research Institute, Frankfurt am Main, Germany. KerstinTusch@gmx.de.
Hendrik ScheweDECHEMA Research Institute, Frankfurt am Main, Germany. schewe@dechema.de.
Markus BuchhauptDECHEMA Research Institute, Frankfurt am Main, Germany. buchhaupt@dechema.de.
Jens SchraderDECHEMA Research Institute, Frankfurt am Main, Germany. schrader@dechema.de.
DECHEMA-ForschungsinstitutSociety for Chemical Engineering and Biotechnology · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProduction of monoterpenoids as valuable chemicals using recombinant microbes is a growing field of interest. Unfortunately, antimicrobial activity of most monoterpenoids hampers a wide application of microorganisms for their production. Strains of Pseudomonas putida, a fast growing and metabolically versatile bacterium, often show an outstanding high tolerance towards organic solvents and other toxic compounds. Therefore, Pseudomonas putida constitutes an attractive alternative host in comparison to conventionally used microorganisms. Here, metabolic engineering of solvent tolerant Pseudomonas putida as a novel microbial cell factory for de novo production of monoterpenoids is reported for the first time, exemplified by geranic acid production from glycerol as carbon source. The monoterpenoic acid is an attractive compound for application in the flavor, fragrance, cosmetics and agro industries.

resultsA comparison between Escherichia coli, Saccharomyces cerevisiae and Pseudomonas putida concerning the ability to grow in the presence of geranic acid revealed that the pseudomonad bears a superior resilience compared to the conventionally used microbes. Moreover, Pseudomonas putida DSM 12264 wildtype strain efficiently oxidized externally added geraniol to geranic acid with no further degradation. Omitting external dosage of geraniol but functionally expressing geraniol synthase (GES) from Ocimum basilicum, a first proof-of-concept for de novo biosynthesis of 1.35 mg/L geranic acid in P. putida DSM 12264 was achieved. Doubling the amount of glycerol resulted in twice the amount of product. Co-expression of the six genes of the mevalonate pathway from Myxococcus xanthus to establish flux from acetyl-CoA to the universal terpenoid precursor isopentenylpyrophosphate yielded 36 mg/L geranic acid in shake flask experiments. In the bioreactor, the recombinant strain produced 193 mg/L of geranic acid under fed-batch conditions within 48 h.

conclusionMetabolic engineering turned Pseudomonas putida DSM 12264, a versatile monoterpenoid oxidation biocatalyst, into an efficient microbial cell factory for de novo geranic acid production. Improvements by metabolic and process engineering are expected to further increase the product concentration. To the best of the authors' knowledge, this is the first example of a de novo production of a monoterpenoid with Pseudomonas putida and of a microbial monoterpenoic acid synthesis in general.

Indexed as

Metabolic EngineeringEscherichia coliMonoterpenesPseudomonas putidaSaccharomyces cerevisiaeTerpenesdecaprenoic acidMonoterpenesTerpenes

Identifiers

PMID25471523
PMCPMC4266966
OpenAlexW2133984086

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.